From single excipients to dual excipient platforms in dry powder inhaler products

Jagdeep Shur; Robert Price; David Lewis; Paul M. Young; Grahame Woollam; Dilraj Singh; Stephen Edge

doi:10.1016/j.ijpharm.2016.05.057

From single excipients to dual excipient platforms in dry powder inhaler products

Jagdeep Shur, Robert Price, David Lewis, Paul M. Young, Grahame Woollam, Dilraj Singh, Stephen Edge

Department of Life Sciences

Research output: Contribution to journal › Article › peer-review

42 Citations (SciVal)

456 Downloads (Pure)

Abstract

Recent years have seen a marked diversification of excipient based formulation strategies used for the development and commercialisation of dry powder inhaler (DPI) products. These innovative approaches not only provide benefits to patients and health care professionals through the availability of a wider range of therapeutic DPI products, but, importantly, also allow formulators to exploit the potential opportunities that excipients provide for the development of DPIs. Whilst many DPI products have, and continue to be developed using a single formulation excipient, the commercialisation of DPI products which contain the two excipients lactose monohydrate and magnesium stearate, namely the ‘dual excipient platform’ has recently been achieved. This article provides an overview of the background and current status of the development of such ‘dual excipient platform’ based DPI products.

Original language	English
Pages (from-to)	374-383
Journal	International Journal of Pharmaceutics
Volume	514
Issue number	2
Early online date	1 Jun 2016
DOIs	https://doi.org/10.1016/j.ijpharm.2016.05.057
Publication status	Published - 5 Dec 2016

Access to Document

10.1016/j.ijpharm.2016.05.057

Accepted PaperAccepted author manuscript, 379 KBLicence: CC BY-NC-ND

Cite this

@article{35fd742607974eb98f91cdc17803bb26,

title = "From single excipients to dual excipient platforms in dry powder inhaler products",

abstract = "Recent years have seen a marked diversification of excipient based formulation strategies used for the development and commercialisation of dry powder inhaler (DPI) products. These innovative approaches not only provide benefits to patients and health care professionals through the availability of a wider range of therapeutic DPI products, but, importantly, also allow formulators to exploit the potential opportunities that excipients provide for the development of DPIs. Whilst many DPI products have, and continue to be developed using a single formulation excipient, the commercialisation of DPI products which contain the two excipients lactose monohydrate and magnesium stearate, namely the {\textquoteleft}dual excipient platform{\textquoteright} has recently been achieved. This article provides an overview of the background and current status of the development of such {\textquoteleft}dual excipient platform{\textquoteright} based DPI products.",

author = "Jagdeep Shur and Robert Price and David Lewis and Young, {Paul M.} and Grahame Woollam and Dilraj Singh and Stephen Edge",

year = "2016",

month = dec,

day = "5",

doi = "10.1016/j.ijpharm.2016.05.057",

language = "English",

volume = "514",

pages = "374--383",

journal = "International Journal of Pharmaceutics",

issn = "0378-5173",

publisher = "Elsevier B.V.",

number = "2",

}

TY - JOUR

T1 - From single excipients to dual excipient platforms in dry powder inhaler products

AU - Shur, Jagdeep

AU - Price, Robert

AU - Lewis, David

AU - Young, Paul M.

AU - Woollam, Grahame

AU - Singh, Dilraj

AU - Edge, Stephen

PY - 2016/12/5

Y1 - 2016/12/5

N2 - Recent years have seen a marked diversification of excipient based formulation strategies used for the development and commercialisation of dry powder inhaler (DPI) products. These innovative approaches not only provide benefits to patients and health care professionals through the availability of a wider range of therapeutic DPI products, but, importantly, also allow formulators to exploit the potential opportunities that excipients provide for the development of DPIs. Whilst many DPI products have, and continue to be developed using a single formulation excipient, the commercialisation of DPI products which contain the two excipients lactose monohydrate and magnesium stearate, namely the ‘dual excipient platform’ has recently been achieved. This article provides an overview of the background and current status of the development of such ‘dual excipient platform’ based DPI products.

AB - Recent years have seen a marked diversification of excipient based formulation strategies used for the development and commercialisation of dry powder inhaler (DPI) products. These innovative approaches not only provide benefits to patients and health care professionals through the availability of a wider range of therapeutic DPI products, but, importantly, also allow formulators to exploit the potential opportunities that excipients provide for the development of DPIs. Whilst many DPI products have, and continue to be developed using a single formulation excipient, the commercialisation of DPI products which contain the two excipients lactose monohydrate and magnesium stearate, namely the ‘dual excipient platform’ has recently been achieved. This article provides an overview of the background and current status of the development of such ‘dual excipient platform’ based DPI products.

UR - http://dx.doi.org/10.1016/j.ijpharm.2016.05.057

U2 - 10.1016/j.ijpharm.2016.05.057

DO - 10.1016/j.ijpharm.2016.05.057

M3 - Article

SN - 0378-5173

VL - 514

SP - 374

EP - 383

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

IS - 2

ER -

From single excipients to dual excipient platforms in dry powder inhaler products

Abstract

Access to Document

Other files and links

Fingerprint

Cite this